194 related articles for article (PubMed ID: 31993368)
1. Targeting BET Proteins With a PROTAC Molecule Elicits Potent Anticancer Activity in HCC Cells.
Zhang H; Li G; Zhang Y; Shi J; Yan B; Tang H; Chen S; Zhang J; Wen P; Wang Z; Pang C; Li J; Guo W; Zhang S
Front Oncol; 2019; 9():1471. PubMed ID: 31993368
[No Abstract] [Full Text] [Related]
2. PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis.
Shi C; Zhang H; Wang P; Wang K; Xu D; Wang H; Yin L; Zhang S; Zhang Y
Cell Death Dis; 2019 Oct; 10(11):815. PubMed ID: 31653826
[TBL] [Abstract][Full Text] [Related]
3. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells.
Sun B; Fiskus W; Qian Y; Rajapakshe K; Raina K; Coleman KG; Crew AP; Shen A; Saenz DT; Mill CP; Nowak AJ; Jain N; Zhang L; Wang M; Khoury JD; Coarfa C; Crews CM; Bhalla KN
Leukemia; 2018 Feb; 32(2):343-352. PubMed ID: 28663582
[TBL] [Abstract][Full Text] [Related]
4. Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer.
Bai L; Zhou B; Yang CY; Ji J; McEachern D; Przybranowski S; Jiang H; Hu J; Xu F; Zhao Y; Liu L; Fernandez-Salas E; Xu J; Dou Y; Wen B; Sun D; Meagher J; Stuckey J; Hayes DF; Li S; Ellis MJ; Wang S
Cancer Res; 2017 May; 77(9):2476-2487. PubMed ID: 28209615
[TBL] [Abstract][Full Text] [Related]
5. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
[TBL] [Abstract][Full Text] [Related]
6. Oridonin synergistically enhances JQ1-triggered apoptosis in hepatocellular cancer cells through mitochondrial pathway.
Zhang HP; Li GQ; Guo WZ; Chen GH; Tang HW; Yan B; Li J; Zhang JK; Wen PH; Wang ZH; Lv JF; Zhang SJ
Oncotarget; 2017 Dec; 8(63):106833-106843. PubMed ID: 29290992
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
8. PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of
Li Z; Lim SL; Tao Y; Li X; Xie Y; Yang C; Zhang Z; Jiang Y; Zhang X; Cao X; Wang H; Qian G; Wu Y; Li M; Fang F; Liu Y; Fu M; Ding X; Zhu Z; Lv H; Lu J; Xiao S; Hu S; Pan J
Front Oncol; 2020; 10():574525. PubMed ID: 33324552
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
Zhou B; Hu J; Xu F; Chen Z; Bai L; Fernandez-Salas E; Lin M; Liu L; Yang CY; Zhao Y; McEachern D; Przybranowski S; Wen B; Sun D; Wang S
J Med Chem; 2018 Jan; 61(2):462-481. PubMed ID: 28339196
[TBL] [Abstract][Full Text] [Related]
10. EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins.
Gollavilli PN; Pawar A; Wilder-Romans K; Natesan R; Engelke CG; Dommeti VL; Krishnamurthy PM; Nallasivam A; Apel IJ; Xu T; Qin ZS; Feng FY; Asangani IA
Cancer Res; 2018 Aug; 78(16):4760-4773. PubMed ID: 29898995
[TBL] [Abstract][Full Text] [Related]
11. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
Noblejas-López MDM; Nieto-Jimenez C; Burgos M; Gómez-Juárez M; Montero JC; Esparís-Ogando A; Pandiella A; Galán-Moya EM; Ocaña A
J Exp Clin Cancer Res; 2019 Aug; 38(1):383. PubMed ID: 31470872
[TBL] [Abstract][Full Text] [Related]
12. BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade.
Tong J; Tan X; Risnik D; Gao M; Song X; Ermine K; Shen L; Wang S; Yu J; Zhang L
Oncogene; 2021 Dec; 40(48):6566-6578. PubMed ID: 34615996
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of Mcl-1 inhibits JQ1-triggered anticancer activity in hepatocellular carcinoma cells.
Zhang HP; Li GQ; Zhang Y; Guo WZ; Zhang JK; Li J; Lv JF; Zhang SJ
Biochem Biophys Res Commun; 2018 Jan; 495(4):2456-2461. PubMed ID: 29287727
[TBL] [Abstract][Full Text] [Related]
14. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.
Zhang X; Lee HC; Shirazi F; Baladandayuthapani V; Lin H; Kuiatse I; Wang H; Jones RJ; Berkova Z; Singh RK; Lu J; Qian Y; Raina K; Coleman KG; Crews CM; Li B; Wang H; Hailemichael Y; Thomas SK; Wang Z; Davis RE; Orlowski RZ
Leukemia; 2018 Oct; 32(10):2224-2239. PubMed ID: 29581547
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
16. ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression.
Deng Y; Yu C; Chen L; Zhang X; Lei Q; Liu Q; Cai G; Liu F
Front Pharmacol; 2022; 13():858901. PubMed ID: 35600879
[TBL] [Abstract][Full Text] [Related]
17. Selective degradation of BET proteins with dBET1, a proteolysis-targeting chimera, potently reduces pro-inflammatory responses in lipopolysaccharide-activated microglia.
DeMars KM; Yang C; Castro-Rivera CI; Candelario-Jalil E
Biochem Biophys Res Commun; 2018 Feb; 497(1):410-415. PubMed ID: 29448097
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
Zhou X; Zhu A; Gu X; Xie G
Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
[TBL] [Abstract][Full Text] [Related]
19. Total alkaloids of Rubus aleaefolius Poir inhibit hepatocellular carcinoma growth in vivo and in vitro via activation of mitochondrial-dependent apoptosis.
Zhao J; Chen X; Lin W; Wu G; Zhuang Q; Zhong X; Hong Z; Peng J
Int J Oncol; 2013 Mar; 42(3):971-8. PubMed ID: 23338043
[TBL] [Abstract][Full Text] [Related]
20. Potent bromodomain and extraterminal domain inhibitor JAB-8263 suppresses MYC expression and exerts anti-tumor activity in colorectal cancer models.
Liu XM; Xia SY; Long W; Li HJ; Yang GQ; Sun W; Li SY; Du XH
World J Gastrointest Oncol; 2023 Feb; 15(2):332-342. PubMed ID: 36908321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]